Oasmia Pharmaceutical AB
The Oasmia Pharmaceutical Annual Report is now published
DGAP-News: Oasmia Pharmaceutical AB 21.08.2014 / 13:16 --------------------------------------------------------------------- Uppsala, Sweden, 2014-08-21 13:16 CEST (GLOBE NEWSWIRE) -- The Oasmia Annual Report for the fiscal year 2013/2014 is now available at the company website www.oasmia.com. About Oasmia Pharmaceutical AB Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics, which in comparison with current alternatives show improved properties, reduced side effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365). Mikael Widell, Vice President Communications Mobile: +46 70 311 99 60 E-mail: mikael.widell@oasmia.com News Source: NASDAQ OMX --------------------------------------------------------------------- 21.08.2014 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: Oasmia Pharmaceutical AB Sweden ISIN: SE0000722365 End of News DGAP News-Service --------------------------------------------------------------------- 283348 21.08.2014
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden